CAS: 252061-94-2; 6-(Benzyloxy)-1,2,3,4-Tetrahydroisoquinoline
- 英文名称6-(Benzyloxy)-1,2,3,4-Tetrahydroisoquinoline
- 中文名称6-(苄氧基)-1,2,3,4-四氢异喹啉
- IUPAC名称6-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline
- 其它别名7-(Benzyloxy)-1,2,3,4-Tetrahydroisoquinoline; 6-(Benzyloxy)-1,2,3,4-Tetrahydroisoquinoline; Isoquinoline, 1,2,3,4-Tetrahydro-6-(Phenylmethoxy)-; 7-Phenylmethoxy-1,2,3,4-Tetrahydroisoquinoline
- CAS编号252061-94-2
- MFCD编号:MFCD17966681
- EINECS号:818-876-5
- 分子式:C16H17NO分子量:239.32
- 产品CID: 1210464
MSDS等安全信息
欧盟法规
C&L通报上下游产品
formaldehyd 2-(4-(benzyloxy)phenyl)ethanamine 3-methoxy-benzaldehyde 1-methoxy-3-(2-nitrovinyl)benzene H-isoquinolin-2-yl)-acetic acid tert-butyl ester(6-benzyloxy-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid tert-butyl ester H-isoquinolin-2-yl]-acetic acid tert-butyl ester[6-(4-cyano-benzyloxy)-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester tert-butoxycarbonylamino-imino-methyl)-benzyloxy]-3,4-dihydro-1H-isoquinolin-2-yl}-acetic acid tert-butyl ester{6-[4-(tert-butoxycarbonylamino-imino-methyl)-benzyloxy]-3,4-dihydro-1H-isoquinolin-2-yl}-acetic acid tert-butyl ester 6-benzyloxy-2-(3-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline合成工艺路线路线简述
- 合成目标产物 7-(Benzyloxy)-1,2,3,4-Tetrahydroisoquinoline 主要起始原料 2(1H)-Isoquinolinecarboxylic Acid, 3,4-Dihydro-6-(Phenylmethoxy)-, 1,1-Dimethylethyl Ester
- (文献来源)合成步骤主要原料 2(1H)-Isoquinolinecarboxylic Acid, 3,4-Dihydro-6-(Phenylmethoxy)-, 1,1-Dimethylethyl Ester
海关参考信息
- 2902600000-乙苯
2905110000-甲醇
2906210000-苄醇
2908199090-其他酚的卤化衍生物 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12304912-B2
优先权日:2020-07-28
标 题 :Fused bicyclic RAF inhibitors and methods for use thereof
发明人：BELFIELD ANDREW; JONES CLIFFORD DAVID; MARGATHE JEAN-FRANÇOIS; COLLETTO CHIARA
权利人:JAZZ PHARMACEUTICALS IRELAND LTD
摘要:The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.
